Scarica l'app Stockscreener
4.985
0.10%
-0.005
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TSVT Giù?
Forum
Previsione
Precedente Chiudi:
$4.99
Aprire:
$4.98
Volume 24 ore:
108.03K
Relative Volume:
0.09
Capitalizzazione di mercato:
$261.17M
Reddito:
$44.12M
Utile/perdita netta:
$-156.25M
Rapporto P/E:
-1.6238
EPS:
-3.07
Flusso di cassa netto:
$-154.61M
1 W Prestazione:
-0.10%
1M Prestazione:
+0.71%
6M Prestazione:
+3.64%
1 anno Prestazione:
+8.61%
Intervallo 1D:
$4.98
$4.99
Intervallo di 1 settimana:
$4.97
$4.99
Portata 52W:
$2.29
$5.30
2 Seventy Bio Inc Stock (TSVT) Company Profile
Nome
2 Seventy Bio Inc
Settore
Industria
Telefono
339-499-9300
Indirizzo
60 BINNEY STREET, CAMBRIDGE
Confronta TSVT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TSVT
2 Seventy Bio Inc
|
4.985 | 261.17M | 44.12M | -156.25M | -154.61M | -3.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.50 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.11 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
629.64 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.63 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
248.31 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-06 | Downgrade | Goldman | Neutral → Sell |
| 2024-01-31 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-01-31 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-30 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-10-12 | Iniziato | Citigroup | Buy |
| 2023-09-13 | Downgrade | Goldman | Buy → Neutral |
| 2023-09-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-28 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-31 | Iniziato | Guggenheim | Buy |
| 2022-05-02 | Iniziato | Goldman | Buy |
| 2022-02-10 | Iniziato | SVB Leerink | Outperform |
| 2022-01-06 | Iniziato | Cowen | Outperform |
| 2021-11-09 | Iniziato | Canaccord Genuity | Buy |
| 2021-11-08 | Iniziato | Morgan Stanley | Overweight |
| 2021-11-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
2 Seventy Bio Inc Borsa (TSVT) Ultime notizie
American Century Companies Inc. Boosts Stake in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Price Target at $6.67 - Defense World
Charles Schwab Investment Management Inc. Has $1.26 Million Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Bluebird gets rival takeout offer from Ayrmid - BioPharma Dive
Bristol Myers Squibb to Acquire 2seventy bio for $5.00 Cash Per Share: Q4 Results Released - Stock Titan
Bristol Meyers Squibb to Acquire 2seventy bio - Contract Pharma
2seventy bio, Inc. (NASDAQ:TSVT) Receives $7.20 Consensus PT from Analysts - Defense World
Bristol Myers Squibb scoops up 2seventy bio for $286M - The Business Journals
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire
Rhumbline Advisers Has $249,000 Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2Seventy Bio at TD Cowen Conference: Strategic Growth and Challenges - Investing.com
Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Target Price at $7.20 - Defense World
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results - Business Wire
Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH - Managed Healthcare Executive
Weiss Ratings Reaffirms “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT) - Defense World
Barclays PLC Sells 132,019 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Fmr LLC Has $701,000 Stock Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2 Seventy Bio Inc Azioni (TSVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2 Seventy Bio Inc Azioni (TSVT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Baird William D III | President and CEO |
Mar 17 '25 |
Sale |
4.95 |
5,092 |
25,180 |
1,121,034 |
| Eatwell Victoria | Chief Financial Officer |
Mar 17 '25 |
Sale |
4.95 |
2,592 |
12,817 |
444,387 |
| Kynam Global Healthcare Master | 10% Owner |
Mar 11 '25 |
Sale |
4.93 |
11,095,936 |
54,702,964 |
0 |
| Kynam Global Healthcare Master | 10% Owner |
Mar 11 '25 |
Sale |
4.93 |
5,142,111 |
25,350,607 |
0 |
| Snow Jessica | See Remarks |
Jan 06 '25 |
Sale |
2.79 |
5,114 |
14,289 |
147,365 |
| Snow Jessica | See Remarks |
Jan 03 '25 |
Sale |
2.94 |
1,000 |
2,936 |
152,479 |
| Snow Jessica | See Remarks |
Jan 07 '25 |
Sale |
2.64 |
186 |
491 |
147,179 |
| Leschly Nick | Director |
Jan 03 '25 |
Sale |
2.94 |
85,978 |
252,423 |
1,234,498 |
| Leschly Nick | Director |
Jan 06 '25 |
Sale |
2.78 |
892 |
2,478 |
1,233,606 |
| Eatwell Victoria | Chief Financial Officer |
Jan 03 '25 |
Sale |
2.94 |
1,013 |
2,974 |
339,076 |
1.36%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):